GE Healthcare and HeartFlow Announce Global Cardiovascular Collaboration

GE Healthcare Logo

GE Healthcare and HeartFlow Inc. announced at SCCT2017, the annual scientific meeting of the Society of Cardiovascular Computed Tomography, that they have entered into a global collaboration agreement with the goal of increasing the clinical availability and adoption of HeartFlow FFRct, a proprietary technology that helps clinicians diagnose and treat patients with suspected coronary artery disease (CAD).

The collaboration will involve computed tomography (CT) scanners from GE Healthcare with HeartFlow FFRct,a technology that provides insight into both the extent of CAD and the impact of the disease on blood flow to the heart. HeartFlow FFRct is designed to enable clinicians to select a definitive, personalized treatment plan for each patient and reduce the need for additional invasive testing. The agreement will initially focus on the United States, with plans to expand into other markets in the future.

“GE has collaborated with HeartFlow over the last five years, and this agreement reinforces our joint commitment to patients worldwide,” said Scott Schubert, general manager, global premium CT, GE Healthcare. “Along with our industry-leading cardiac CT systems and clinical applications, GE can now offer HeartFlow FFRct as an option for health care providers who strive to deliver the highest standards in clinical care while reducing costs.”

“This agreement with GE will help bring our game-changing non-invasive technology into the mainstream of cardiac care at thousands of hospitals that are already using state-of-the-art CT systems from GE, which provide exceptional image quality,” said John H. Stevens, M.D., president and chief executive officer of HeartFlow. “By collaborating, we can ensure that HeartFlow FFRct can be easily integrated into existing CAD protocols and more readily transform the care of patients with suspected and potentially life-threatening CAD.”